Compare · APGB vs IBER
APGB vs IBER
Side-by-side comparison of Apollo Strategic Growth Capital II (APGB) and Ibere Pharmaceuticals (IBER): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APGB and IBER operate in Blank Checks (Finance), so they compete in similar markets.
- APGB is the larger of the two at $836.6M, about 5.0x IBER ($167.2M).
Apollo Strategic Growth Capital II
Apollo Strategic Growth Capital II intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was formerly known as APH I (Sub I), Ltd. and changed its name to Apollo Strategic Growth Capital II in December 2020. Apollo Strategic Growth Capital II was incorporated in 2008 and is based in New York, New York.
Ibere Pharmaceuticals
Ibere Pharmaceuticals focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in Philadelphia, Pennsylvania.
Latest APGB
- SEC Form SC 13G/A filed by Apollo Strategic Growth Capital II (Amendment)
- SEC Form SC 13G/A filed by Apollo Strategic Growth Capital II (Amendment)
- SEC Form SC 13G filed by Apollo Strategic Growth Capital II
- SEC Form 15-12G filed by Apollo Strategic Growth Capital II
- SEC Form 25-NSE filed by Apollo Strategic Growth Capital II
- SEC Form 10-Q filed by Apollo Strategic Growth Capital II
- Apollo Strategic Growth Capital II filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Apollo Strategic Growth Capital II Will Redeem Its Public Shares And Will Not Consummate An Initial Business Combination; Per-Share Redemption Price For The Public Shares Will Be ~$10.58
- Apollo Strategic Growth Capital II Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination
- SEC Form 10-Q filed by Apollo Strategic Growth Capital II
Latest IBER
- SEC Form 15-12G filed by Ibere Pharmaceuticals
- SEC Form 25-NSE filed by Ibere Pharmaceuticals
- Ibere Pharmaceuticals filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Ibere Pharmaceuticals Will Redeem All Outstanding Ordinary Shares Included In Units Issued In IPO Effective As Of Close Of Business On March 2; Per-Share Redemption Price For Public Shares Will Be ~$10.17; Expects That NYSE Will File Form 25 To Delist Co
- SEC Form SC 13G filed by Ibere Pharmaceuticals
- SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
- SEC Form SC 13G filed by Ibere Pharmaceuticals
- SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
- SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
- SEC Form 10-Q filed by Ibere Pharmaceuticals